/
/
/

Marksans Pharma Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
%
Name
Net Revenue
Other Income
Total Revenue
Total Expenditure
Operating Profit
Interest Expense
PBT
Net Profit
Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022Dec 2021Sep 2021Jun 2021Mar 2021Dec 2020Sep 2020Jun 2020Mar 2020Dec 2019Sep 2019Jun 2019Mar 2019Dec 2018Sep 2018Jun 2018Mar 2018Dec 2017Sep 2017Jun 2017Mar 2017Dec 2016Sep 2016Jun 2016Mar 2016Dec 2015Sep 2015Jun 2015Mar 2015Dec 2014Sep 2014Jun 2014Mar 2014Dec 2013Sep 2013Jun 2013Mar 2013Dec 2012Sep 2012
₹841 Cr₹856 Cr₹754 Cr₹720 Cr₹620 Cr₹708 Cr₹682 Cr₹642 Cr₹591 Cr₹560 Cr₹586 Cr₹531 Cr₹500 Cr₹486 Cr₹480 Cr₹453 Cr₹434 Cr₹418 Cr₹363 Cr₹361 Cr₹349 Cr₹330 Cr₹358 Cr₹356 Cr₹331 Cr₹335 Cr₹288 Cr₹256 Cr₹245 Cr₹247 Cr₹248 Cr₹269 Cr₹235 Cr₹199 Cr₹218 Cr₹274 Cr₹221 Cr₹178 Cr₹215 Cr₹180 Cr₹187 Cr₹217 Cr₹218 Cr₹256 Cr₹212 Cr₹174 Cr₹213 Cr₹211 Cr₹202 Cr₹160 Cr₹169 Cr₹161 Cr₹144 Cr₹124 Cr₹115 Cr₹109 Cr
₹25 Cr₹35 Cr₹20 Cr₹22 Cr₹6 Cr₹15 Cr₹36 Cr-₹7 L₹15 Cr₹17 Cr₹5 Cr₹19 Cr₹10 Cr₹11 Cr₹18 Cr₹14 Cr₹16 Cr₹15 Cr₹12 Cr₹9 Cr₹6 Cr₹6 Cr-₹3 Cr₹4 Cr₹18 L₹3 L₹3 L₹8 Cr₹2 Cr₹10 Cr₹16 L-₹80 L₹3 Cr₹0₹39 L₹0₹4 L₹7 Cr₹0₹7 Cr₹1 L₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0
₹866 Cr₹891 Cr₹775 Cr₹742 Cr₹626 Cr₹724 Cr₹718 Cr₹642 Cr₹606 Cr₹577 Cr₹591 Cr₹550 Cr₹510 Cr₹497 Cr₹497 Cr₹467 Cr₹450 Cr₹433 Cr₹375 Cr₹370 Cr₹355 Cr₹336 Cr₹355 Cr₹360 Cr₹331 Cr₹335 Cr₹288 Cr₹264 Cr₹247 Cr₹257 Cr₹249 Cr₹268 Cr₹238 Cr₹199 Cr₹219 Cr₹274 Cr₹221 Cr₹185 Cr₹215 Cr₹187 Cr₹187 Cr₹217 Cr₹218 Cr₹256 Cr₹212 Cr₹174 Cr₹213 Cr₹211 Cr₹202 Cr₹160 Cr₹169 Cr₹161 Cr₹144 Cr₹124 Cr₹115 Cr₹109 Cr
₹653 Cr₹685 Cr₹618 Cr₹603 Cr₹543 Cr₹604 Cr₹572 Cr₹515 Cr₹483 Cr₹471 Cr₹475 Cr₹435 Cr₹412 Cr₹390 Cr₹416 Cr₹386 Cr₹372 Cr₹376 Cr₹313 Cr₹308 Cr₹279 Cr₹236 Cr₹276 Cr₹292 Cr₹268 Cr₹276 Cr₹248 Cr₹228 Cr₹217 Cr₹238 Cr₹217 Cr₹237 Cr₹206 Cr₹202 Cr₹196 Cr₹256 Cr₹200 Cr₹185 Cr₹200 Cr₹186 Cr₹178 Cr₹214 Cr₹197 Cr₹210 Cr₹165 Cr₹136 Cr₹165 Cr₹164 Cr₹164 Cr₹139 Cr₹139 Cr₹135 Cr₹121 Cr₹83 Cr₹102 Cr₹91 Cr
₹238 Cr₹231 Cr₹181 Cr₹166 Cr₹106 Cr₹142 Cr₹167 Cr₹147 Cr₹143 Cr₹126 Cr₹138 Cr₹133 Cr₹112 Cr₹121 Cr₹94 Cr₹94 Cr₹89 Cr₹79 Cr₹70 Cr₹69 Cr₹83 Cr₹101 Cr₹88 Cr₹87 Cr₹70 Cr₹69 Cr₹47 Cr₹41 Cr₹35 Cr₹25 Cr₹36 Cr₹36 Cr₹39 Cr₹4 Cr₹29 Cr₹25 Cr₹29 Cr₹8 Cr₹27 Cr₹7 Cr₹13 Cr₹11 Cr₹31 Cr₹51 Cr₹52 Cr₹42 Cr₹52 Cr₹51 Cr₹43 Cr₹24 Cr₹36 Cr₹30 Cr₹26 Cr₹42 Cr₹19 Cr₹23 Cr
₹7 Cr₹6 Cr₹6 Cr₹6 Cr₹6 Cr₹3 Cr₹3 Cr₹3 Cr₹3 Cr₹5 Cr₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr₹2 Cr₹5 Cr₹95 L₹2 Cr₹97 L₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹3 Cr₹2 Cr₹3 Cr₹2 Cr₹3 Cr₹2 Cr₹2 Cr₹2 Cr₹1 Cr₹1 Cr₹2 Cr₹2 Cr₹3 Cr₹3 Cr₹1 Cr₹6 Cr₹5 Cr₹4 Cr₹4 Cr₹3 Cr₹4 Cr₹3 Cr₹4 Cr₹4 Cr₹3 Cr
₹207 Cr₹200 Cr₹151 Cr₹133 Cr₹77 Cr₹116 Cr₹143 Cr₹125 Cr₹120 Cr₹100 Cr₹113 Cr₹114 Cr₹97 Cr₹104 Cr₹79 Cr₹78 Cr₹76 Cr₹53 Cr₹60 Cr₹60 Cr₹75 Cr₹97 Cr₹78 Cr₹66 Cr₹61 Cr₹58 Cr₹38 Cr₹34 Cr₹28 Cr₹17 Cr₹30 Cr₹28 Cr₹30 Cr-₹6 Cr₹21 Cr₹15 Cr₹20 Cr-₹1 Cr₹13 Cr-₹8 L₹7 Cr₹43 L₹18 Cr₹43 Cr₹45 Cr₹36 Cr₹42 Cr₹42 Cr₹35 Cr₹17 Cr₹27 Cr₹22 Cr₹20 Cr₹37 Cr₹9 Cr₹15 Cr
₹159 Cr₹149 Cr₹114 Cr₹99 Cr₹58 Cr₹91 Cr₹105 Cr₹98 Cr₹89 Cr₹78 Cr₹83 Cr₹84 Cr₹70 Cr₹83 Cr₹62 Cr₹60 Cr₹60 Cr₹30 Cr₹48 Cr₹46 Cr₹63 Cr₹79 Cr₹59 Cr₹51 Cr₹49 Cr₹43 Cr₹30 Cr₹26 Cr₹22 Cr₹10 Cr₹25 Cr₹21 Cr₹25 Cr-₹6 Cr₹17 Cr₹10 Cr₹14 Cr-₹3 Cr₹12 Cr₹75 L₹5 Cr-₹4 Cr₹19 Cr₹36 Cr₹32 Cr₹26 Cr₹28 Cr₹32 Cr₹26 Cr₹11 Cr₹23 Cr₹21 Cr₹19 Cr₹42 Cr₹9 Cr₹15 Cr

Share Price Live Stats

Open (₹)333.00
Volume (₹)3.68 L
High (₹)333.30
Upper Circuit398.60
Low (₹)326.20
Lower Circuit265.80
Prev Close332.20
52W High (₹)345.50
Price329.80
52W Low (₹)155.00

Share Market Cap & Key Ratios Overview

M.Cap (₹)15036.00 Cr
Div. Yield (%)0.27
PE Ratio29.10
Debt to Equity0.01
Price to Book2.36
Book Value66.64
EPS (TTM)11.40
Face Value1.00
ROE (%)15.31

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
LUPINNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
MARKSANSNSE
LTP
1W Low
1W High
Market cap (₹)
1906.1-13.9 (-0.72%)
1905
1984.80
4,56,833Cr
9153.5-85.5 (-0.93%)
9087
9467
2,45,426Cr
4900.5-149.5 (-2.96%)
4886.50
5066
1,87,320Cr
1129.2-61.8 (-5.19%)
1125.10
1187
1,13,217Cr
1378-45.5 (-3.20%)
1376.70
1426.10
1,12,212Cr
1862.1-76.4 (-3.94%)
1811.70
1949
1,01,155Cr
2119.4-52.1 (-2.40%)
2118.10
2192
97,626Cr
2359.2-23.7 (-0.99%)
2341.20
2419.20
96,859Cr
1158.6-19.4 (-1.65%)
1154.40
1179.90
96,406Cr
1630.3-15 (-0.91%)
1622.60
1717
93,614Cr
329.8+0.1 (0.03%)
313.10
341
15,036Cr

Key Highlights of Marksans Pharma Ltd’s P&L

In 2026-03-31, Marksans Pharma Ltd reported total revenue of ₹3033.47Cr, compared with ₹2689.17Cr in 2025-03-31, reflecting Marksans Pharma Ltd turnover.

Depreciation was ₹98.63Cr and finance costs were ₹24.13Cr in 2026-03-31

Profit Before Tax (PBT) has been ₹560.55Cr in 2026-03-31 as compared to ₹503.97Cr in 2025-03-31.

Net Profit (PAT) was ₹417.9Cr in 2026-03-31 compared with ₹380.57Cr in 2025-03-31.

Earnings per share (EPS) were ₹9.22 in 2026-03-31, compared with ₹8.40 in 2025-03-31.